We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

Hyperglycemia Evaluated as a Risk Factor in Pancreatic Cancer

By LabMedica International staff writers
Posted on 23 Jun 2021
Print article
Image: A blood test for glucose may reveal hyperglycemia which has been evaluated as a risk factor in pancreatic cancer (Photo courtesy of Amit Akirov, MD)
Image: A blood test for glucose may reveal hyperglycemia which has been evaluated as a risk factor in pancreatic cancer (Photo courtesy of Amit Akirov, MD)
Pancreatic ductal adenocarcinoma (pancreatic cancer) has a five-year survival rate of 9%. Most patients are diagnosed with metastatic disease due to late presenting symptoms and only 10% to 20% are able to undergo surgery with a curative intent.

Diabetes mellitus is common in pancreatic cancer patients. At diagnosis, only 14% have a normal fasting glucose and nearly half have diabetes mellitus. Although this is a well-known phenomenon, neither the underlying etiology nor the impact on prognosis has been established.

Medical Scientists mainly from Umeå University (Umeå, Sweden) carried out a prospective nested case-control study that included 182 patients in the analysis after various exclusions. Seventy-four cases had participated more than once, with a total of 310 surveys. Most cases were matched with four control surveys (96%). The object of the study was to determine the risk association between fasting glucose levels and pancreatic cancer using systematically collected prediagnostic blood glucose samples.

Plasma samples were drawn after overnight fasting. Oral glucose tolerance test (OGTT) was performed according to World Health Organization standards, with plasma glucose levels measured at 120 minutes after a 75 gram oral glucose load. The methods of glucose analysis differed slightly over time, i.e. capillary versus venous samples and different bench-top analyzers. Additional clinical data were collected on the pancreatic cancer cases from medical records, including fasting glucose at diagnosis (measured at the time of diagnosis ± three months), TNM Classification of Malignant Tumors stage, tumor grade, survival after diagnosis and treatment.

The investigators reported that the unadjusted risk of developing pancreatic cancer increased with increasing fasting glucose levels (odd ratio [OR] = 1.30). Impaired fasting glucose (≥6.1 mmol/L) was associated with an adjusted risk of 1.77 for developing pancreatic cancer. In subgroup analysis, fasting glucose levels were associated with an increased risk in never-smokers (OR = 4.02) and non-diabetics (OR = 3.08) (non-significant for interaction). The ratio between fasting glucose and BMI was higher among future pancreatic cancer patients and an increased ratio was associated with elevated risk of pancreatic cancer (OR = 1.66). Fasting glucose levels were not associated with TNM stage at diagnosis or survival.

The authors concluded that their nested case-control study showed that fasting glucose levels were associated with pancreatic cancer risk. Impaired fasting glucose in individuals aged >55 is associated with an increased risk. Impaired fasting glucose is an independent risk factor and should be investigated further in pancreatic cancer risk assessment including other risk factors in a larger study population. The study was published on May 15, 2021 in the journal Pancreatology.

Related Links:
Umeå University


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
One Step HbA1c Measuring System
GREENCARE A1c
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test

Print article

Channels

Molecular Diagnostics

view channel
Image: The BIOFIRE® SPOTFIRE® R/ST Panel has received dual 510(k) clearance and CLIA-waiver approval (Photo courtesy of bioMérieux)

Respiratory and Throat Infection PCR Test Detects Multiple Pathogens with Overlapping Symptoms

The COVID-19 pandemic has demonstrated the need for healthcare professionals to have diagnostic tests available as close as possible to the patient, providing actionable results quickly.... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.